JMV 390-1Inhibits multiple neurotensin and neuromedin N degrading enzymes CAS# 148473-36-3 |
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- Purmorphamine
Catalog No.:BCC3641
CAS No.:483367-10-8
- GANT61
Catalog No.:BCC1090
CAS No.:500579-04-4
- GANT 58
Catalog No.:BCC1587
CAS No.:64048-12-0
- GDC-0449 (Vismodegib)
Catalog No.:BCC1285
CAS No.:879085-55-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 148473-36-3 | SDF | Download SDF |
PubChem ID | 5487524 | Appearance | Powder |
Formula | C23H35N3O6 | M.Wt | 449.54 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 0.80 mg/ml in sodium bicarbonate (0.01M) | ||
Sequence | XIL (Modifications: X-1 = N-[(2R)-4-Hydroxyamino)-1,4-di | ||
Chemical Name | (2S)-2-[[(2S,3S)-2-[[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid | ||
SMILES | CCC(C)C(C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=CC=C1)CC(=O)NO | ||
Standard InChIKey | MWZOULASPWUGJJ-NFBUACBFSA-N | ||
Standard InChI | InChI=1S/C23H35N3O6/c1-5-15(4)20(22(29)24-18(23(30)31)11-14(2)3)25-21(28)17(13-19(27)26-32)12-16-9-7-6-8-10-16/h6-10,14-15,17-18,20,32H,5,11-13H2,1-4H3,(H,24,29)(H,25,28)(H,26,27)(H,30,31)/t15-,17+,18-,20-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of the major neurotensin and neuromedin N degrading enzymes (IC50 values are 31, 40, 52 and 58 nM for endopeptidase 24.15, endopeptidase 24.11, leucine aminopeptidase and endopeptidase 24.16 respectively). Exhibits analgesic effects in various nociception assays. |
JMV 390-1 Dilution Calculator
JMV 390-1 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- L-732,138
Catalog No.:BCC6821
CAS No.:148451-96-1
- Prion Protein 106-126 (human)
Catalog No.:BCC6027
CAS No.:148439-49-0
- (+)-Matairesinol
Catalog No.:BCN7021
CAS No.:148409-36-3
- Docetaxel Trihydrate
Catalog No.:BCC1535
CAS No.:148408-66-6
- Secoisolariciresinol Diglucoside
Catalog No.:BCN1212
CAS No.:148244-82-0
- H-Dap-OH.HCl
Catalog No.:BCC3186
CAS No.:1482-97-9
- UNC 0642
Catalog No.:BCC8014
CAS No.:1481677-78-4
- (±)-Epibatidine
Catalog No.:BCC6750
CAS No.:148152-66-3
- trans-2-Tridecene-1,13-dioic acid
Catalog No.:BCN3667
CAS No.:14811-82-6
- Ac-Lys(Fmoc)-OH
Catalog No.:BCC2679
CAS No.:148101-51-3
- Fmoc-Lys(Dnp)-OH
Catalog No.:BCC3519
CAS No.:148083-64-1
- Talc
Catalog No.:BCC4730
CAS No.:14807-96-6
- MNS
Catalog No.:BCC3943
CAS No.:1485-00-3
- GRK2i
Catalog No.:BCC6048
CAS No.:148505-03-7
- Pregabalin
Catalog No.:BCN2175
CAS No.:148553-50-8
- 3,5-Dihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1658
CAS No.:14858-07-2
- 3-O-Methylquercetin tetraacetate
Catalog No.:BCN1659
CAS No.:1486-69-7
- 3-O-Methylquercetin
Catalog No.:BCN1660
CAS No.:1486-70-0
- Fmoc-Prolinol
Catalog No.:BCC2710
CAS No.:148625-77-8
- GR 127935 hydrochloride
Catalog No.:BCC7081
CAS No.:148642-42-6
- L-733,060 hydrochloride
Catalog No.:BCC5707
CAS No.:148687-76-7
- SB 204070
Catalog No.:BCC5752
CAS No.:148688-01-1
- Tyrphostin AG 879
Catalog No.:BCC4514
CAS No.:148741-30-4
- (R)-2-Methylcysteine HCl
Catalog No.:BCC4017
CAS No.:148766-37-4
Effects of thiorphan, bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the recovery of neurotensin and neuromedin N released from mouse hypothalamus.[Pubmed:1454216]
Neurosci Lett. 1992 Aug 17;142(2):200-4.
The effects of the endopeptidase 24.11 ('enkephalinase') inhibitor thiorphan, the aminopeptidase inhibitor bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the K(+)-evoked release of immunoreactive neurotensin and neuromedin N (iNT and iNN) from mouse hypothalamic slices were examined. (JMV 390-1 inhibits several metallopeptidases including endopeptidases 24.11, 24.15 and 24.16, and aminopeptidase N equipotently with Ki values around 50 nM.) Thiorphan increased the recovery of released iNT nearly 2-fold and had no effect on iNN. Bestatin produced a 4-fold increase in iNN recovery and was inactive on iNT. Finally, iNT and iNN recoveries were increased up to 4- and 5-fold, respectively, by JMV 390-1. These results show that in the mouse hypothalamus endopeptidase 24.11 participates with other metalloendopeptidases to the degradation of endogenously released NT while endogenously released NN is principally degraded by aminopeptidase(s).
The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors.[Pubmed:8973585]
Biochem J. 1996 Dec 1;320 ( Pt 2):687-91.
The lethal factor of Bacillus anthracis is central to the pathogenesis of anthrax. Its mechanism of action is still unknown. Recently, on the basis of sequence similarities, we suggested that lethal factor might act similarly to leukotriene A4 hydrolase (LTA4), a bifunctional enzyme also endowed with a metallopeptidase activity. Here we show that some inhibitors of the LTA4 hydrolase and metallopeptidase activities of LTA4 hydrolase also affect the cytotoxicity of the anthrax lethal factor on macrophage cell lines, without interfering with the ability of the lethal factor to enter cells. These results support the proposal that anthrax lethal factor might display in the cytosol of intoxicated cells a peptidase activity similar to that of LTA4 hydrolase.
Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes.[Pubmed:8496905]
J Med Chem. 1993 May 14;36(10):1369-79.
The synthesis of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine (JMV-390-1, 6a), a multipeptidase inhibitor based on the C-terminal sequence common to neurotensin (NT) and neuromedin N (NN), is described. This compound behaves as a full inhibitor of the major NT/NN degrading enzymes in vitro, e.g. endopeptidase 24.16, endopeptidase 24.15, endopeptidase 24.11, and leucine aminopeptidase (type IV-S), in the nanomolar range (IC50's from 30 to 60 nM). Compound 6a was found to increase endogenous recovery of NT and NN from slices of mice hypothalamus depolarized with potassium. In various assays commonly used to select analgesics, e.g. hot-plate test, tail-flick test, acetic acid-induced writhing test, in mice, compound 6a proved to be potent when intracerebroventricularly (icv) injected. The analgesic effects observed were totally (hot-plate test) or largely (tail-flick test) reversed by the opioid antagonist naltrexone. Furthermore, icv injection of compound 6a (10 micrograms/mouse) was found to significantly potentiate the hypothermic effects of NT or NN.